Resources
OPKO Connect offers support for your office on behalf of your patients who have been prescribed Rayaldee® (calcifediol).
Benefits Investigation
OPKO Connect will verify the patient’s insurance coverage for Rayaldee, including identifying
• | Prior authorization requirements |
• | Deductible, co-insurance, and out-of-pocket costs |
Prior Authorization (PA) Assistance

OPKO Connect will assist with any insurance-required PAs for Rayaldee by
• | Completing and submitting insurer-specific PA forms |
• | Confirming receipt of submission by insurance and facilitating a timely review |
• | Providing status from insurance to patients and their healthcare provider’s office |
Support for Appeals if the PA is Denied
OPKO Connect will
• | Confirm the reason for the PA denial and provide options for appeals submission |
• | Supply a letter of medical necessity (LMN) template specific to Rayaldee |
• | Provide appeal status from insurance to patients and their healthcare provider’s office |
Copay Assistance
Eligible, commercially insured patients can fill their Rayaldee prescription for $5 per month until the annual maximum limit is reached.

* | Eligible, commercially insured patients can fill their Rayaldee prescription for $5 per month. |
Patient Assistance Program (PAP)
For patients without Rayaldee pharmacy insurance coverage, OPKO Connect has a patient assistance program offering free medication. Eligibility criteria apply and annual reenrollment is required.
Download the application for patient assistance.
![]() |
|

* | Eligible, commercially insured patients can fill their Rayaldee prescription for $5 per month. |
To receive support for your patients, please complete a Rayaldee Service Request Form (SRF) and return to OPKO Connect.
• | Fax 1-844-660-7083 |
• | Email opkoconnect@rxallcare.com |
OPKO Connect services are available
by phone at 1-844-414-6756
or by email opkoconnect@rxallcare.com
Monday through Friday, 8am to 8pm ET
![]() |
|
|
Mechanism of Action of Rayaldee® (calcifediol) |
Discussion Around Ideal Concentrations for Serum Total 25(OH)D in Patients With Chronic Kidney Disease Stages 3 and 4 (Interview with Dr. Stuart Sprague, DO, FACP, FASN, FNKF) |
|
Importance of Monitoring and Treating Chronic Kidney Disease and Secondary Hyperparathyroidism (Interview with Dr. Charles Bishop, CEO of OPKO Renal Division) |
![]() |
Download a checklist for you to evaluate your patients for SHPT. |
![]() |
Download a resource from the National Kidney Foundation to help you streamline the conversation you have with patients about how kidney disease can lead to bone and heart disease. This information sheet includes reference levels of crucial lab values, treatment, and nutritional considerations. |
![]() |
Download information for patients from the National Kidney Foundation about how kidney disease can lead to bone and heart disease. This information sheet includes a place you can write in the levels of calcium, phosphorus, parathyroid hormone, and vitamin D in your patient's blood. |
![]() |
Download information for patients from the National Kidney Foundation about how kidney disease can lead to bone and heart disease. |
![]() |
Download the KDIGO CKD-MBD Quick Reference Guide, which presents the recommendation statements that were updated in 2017 and those that remained unchanged from 2009. |
Helpful resources
![]() |
Information and resources for healthcare providers about CKD-MBD, SHPT, vitamin D deficiency, and other related conditions | National Kidney Foundation |
Professional associations
![]() |
American Society of Nephrology (ASN) |
![]() |
National Kidney Foundation (NKF) |
![]() |
Renal Physicians Association (RPA) |
Clinical guidelines
![]() |
KDIGO |
![]() |
KDOQI |
News
Coming soon!
Publications
![]() |
Secondary Hyperparathyroidism in a Patient with CKD | Clin J Am Soc Nephrol 2020;15(7):1041-1043. |
![]() |
Aiming Too Low: Reevaluation of Target Concentrations of Serum 25-Hydroxyvitamin D in Secondary Hyperparathyroidism | Am J Nephrol 2019;49(4):281-283. |
![]() |
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease | Am J Nephrol 2019;49(4):284-293. |
![]() |
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease | Am J Nephrol 2016;44(4):316-325. |